+关注
Fufulum
暂无个人介绍
IP属地：未知
9
关注
0
粉丝
0
主题
0
勋章
主贴
热门
Fufulum
2021-12-22
Good
10 Biggest Price Target Changes For Wednesday
Fufulum
2021-12-22
Good
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3570530898848203,"uuid":"3570530898848203","gmtCreate":1607436875716,"gmtModify":1612576962327,"name":"Fufulum","pinyin":"fufulum","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":9,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.26","exceedPercentage":"80.80%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.10%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":691664928,"gmtCreate":1640185209764,"gmtModify":1640185209855,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691664928","repostId":"1188142807","repostType":4,"repost":{"id":"1188142807","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640181395,"share":"https://www.laohu8.com/m/news/1188142807?lang=&edition=full","pubTime":"2021-12-22 21:56","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1188142807","media":"Benzinga","summary":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Researc","content":"<ul>\n <li>Barclays lifted the price target on <b>FactSet Research Systems Inc.</b> from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>\n <li>HC Wainwright & Co. raised the price target on <b>Chimerix, Inc.</b> from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>\n <li>Bernstein raised <b>PACCAR Inc</b> price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>\n <li>Jefferies cut <b>Adagio Therapeutics, Inc.</b> price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>\n <li>Barclays boosted the price target for <b>NIKE, Inc.</b> from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>\n <li>Needham lowered the price target on <b>Cognyte Software Ltd.</b> from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>\n <li>Jefferies cut <b>ALX Oncology Holdings Inc.</b> price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>\n <li>Bernstein reduced the price target for <b>AGCO Corporation</b> from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>\n <li>RBC Capital raised <b>Consolidated Edison, Inc.</b> price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>\n <li>Oppenheimer cut <b>Biogen Inc.</b> price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 21:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Barclays lifted the price target on <b>FactSet Research Systems Inc.</b> from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>\n <li>HC Wainwright & Co. raised the price target on <b>Chimerix, Inc.</b> from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>\n <li>Bernstein raised <b>PACCAR Inc</b> price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>\n <li>Jefferies cut <b>Adagio Therapeutics, Inc.</b> price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>\n <li>Barclays boosted the price target for <b>NIKE, Inc.</b> from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>\n <li>Needham lowered the price target on <b>Cognyte Software Ltd.</b> from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>\n <li>Jefferies cut <b>ALX Oncology Holdings Inc.</b> price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>\n <li>Bernstein reduced the price target for <b>AGCO Corporation</b> from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>\n <li>RBC Capital raised <b>Consolidated Edison, Inc.</b> price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>\n <li>Oppenheimer cut <b>Biogen Inc.</b> price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALXO":"ALX Oncology Holdings","CMRX":"Chimerix Inc.","NKE":"耐克","BIIB":"渤健公司","CGNT":"Cognyte Software Ltd.","FDS":"辉盛研究系统","ED":"爱迪生联合电气","AGCO":"爱科集团","PCAR":"帕卡"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188142807","content_text":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.\nHC Wainwright & Co. raised the price target on Chimerix, Inc. from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.\nBernstein raised PACCAR Inc price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.\nJefferies cut Adagio Therapeutics, Inc. price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.\nBarclays boosted the price target for NIKE, Inc. from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.\nNeedham lowered the price target on Cognyte Software Ltd. from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.\nJefferies cut ALX Oncology Holdings Inc. price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.\nBernstein reduced the price target for AGCO Corporation from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.\nRBC Capital raised Consolidated Edison, Inc. price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.\nOppenheimer cut Biogen Inc. price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691665587,"gmtCreate":1640185187897,"gmtModify":1640185187897,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691665587","repostId":"1165830356","repostType":4,"repost":{"id":"1165830356","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b> has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.</p>\n<ul>\n <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>\n <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>\n <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.</li>\n <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>\n <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>\n <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>\n <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>\n <li><b>Price Action:</b> BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 22:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b> has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.</p>\n<ul>\n <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>\n <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>\n <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.</li>\n <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>\n <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>\n <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>\n <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>\n <li><b>Price Action:</b> BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":691664928,"gmtCreate":1640185209764,"gmtModify":1640185209855,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691664928","repostId":"1188142807","repostType":4,"repost":{"id":"1188142807","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640181395,"share":"https://www.laohu8.com/m/news/1188142807?lang=&edition=full","pubTime":"2021-12-22 21:56","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1188142807","media":"Benzinga","summary":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Researc","content":"<ul>\n <li>Barclays lifted the price target on <b>FactSet Research Systems Inc.</b> from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>\n <li>HC Wainwright & Co. raised the price target on <b>Chimerix, Inc.</b> from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>\n <li>Bernstein raised <b>PACCAR Inc</b> price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>\n <li>Jefferies cut <b>Adagio Therapeutics, Inc.</b> price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>\n <li>Barclays boosted the price target for <b>NIKE, Inc.</b> from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>\n <li>Needham lowered the price target on <b>Cognyte Software Ltd.</b> from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>\n <li>Jefferies cut <b>ALX Oncology Holdings Inc.</b> price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>\n <li>Bernstein reduced the price target for <b>AGCO Corporation</b> from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>\n <li>RBC Capital raised <b>Consolidated Edison, Inc.</b> price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>\n <li>Oppenheimer cut <b>Biogen Inc.</b> price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 21:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Barclays lifted the price target on <b>FactSet Research Systems Inc.</b> from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>\n <li>HC Wainwright & Co. raised the price target on <b>Chimerix, Inc.</b> from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>\n <li>Bernstein raised <b>PACCAR Inc</b> price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>\n <li>Jefferies cut <b>Adagio Therapeutics, Inc.</b> price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>\n <li>Barclays boosted the price target for <b>NIKE, Inc.</b> from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>\n <li>Needham lowered the price target on <b>Cognyte Software Ltd.</b> from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>\n <li>Jefferies cut <b>ALX Oncology Holdings Inc.</b> price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>\n <li>Bernstein reduced the price target for <b>AGCO Corporation</b> from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>\n <li>RBC Capital raised <b>Consolidated Edison, Inc.</b> price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>\n <li>Oppenheimer cut <b>Biogen Inc.</b> price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALXO":"ALX Oncology Holdings","CMRX":"Chimerix Inc.","NKE":"耐克","BIIB":"渤健公司","CGNT":"Cognyte Software Ltd.","FDS":"辉盛研究系统","ED":"爱迪生联合电气","AGCO":"爱科集团","PCAR":"帕卡"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188142807","content_text":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.\nHC Wainwright & Co. raised the price target on Chimerix, Inc. from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.\nBernstein raised PACCAR Inc price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.\nJefferies cut Adagio Therapeutics, Inc. price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.\nBarclays boosted the price target for NIKE, Inc. from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.\nNeedham lowered the price target on Cognyte Software Ltd. from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.\nJefferies cut ALX Oncology Holdings Inc. price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.\nBernstein reduced the price target for AGCO Corporation from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.\nRBC Capital raised Consolidated Edison, Inc. price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.\nOppenheimer cut Biogen Inc. price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691665587,"gmtCreate":1640185187897,"gmtModify":1640185187897,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691665587","repostId":"1165830356","repostType":4,"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
